KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41364689PMC126904822026-Feb-170.98未发现恶性肿瘤人群证据。无 KM 图
Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Sci RepPMID 41702946PMC129138972026-Feb-170.98未发现恶性肿瘤人群证据。已完成
Artificial Intelligence-based characterization of therapeutic response in fluid types and volumes influencing retinal function in neovascular age-related macular degeneration.Sci Rep已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。PMID 41703113PMC130048302026-Feb-170.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41628627无 PMCID2026-Feb-140.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and safety of a novel sodium picosulfate oral tablet in a randomized controlled trial for bowel preparation.World J Gastroenterol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图;Figure 3:非 KM 图。PMID 41695285PMC128982742026-Feb-140.98未发现恶性肿瘤人群证据。无 KM 图
Extended window of relapse recovery in RRMS: an analysis of the DECIDE dataset.J Neurol Neurosurg PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41072954无 PMCID2026-Feb-130.98未发现恶性肿瘤人群证据。无 KM 图
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41196369无 PMCID2026-Feb-120.85The study is a Phase III randomized trial of a drug for a non-oncologic kidney disease. While it meets criteria for human, randomized, phase, drug intervention, and original result, it is not oncology and its primary efficacy endpoint is not a time-to-event outcome.无 KM 图
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41211929无 PMCID2026-Feb-120.95The trial is a randomized, Phase III study of a drug intervention in humans, but it is not an oncology trial (targets IgA nephropathy). Furthermore, the primary and key secondary endpoints (proteinuria reduction, eGFR slope) are not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or hazard ratio analysis.无 KM 图
Memantine to preserve memory and neurocognition following craniospinal irradiation (MEMENTO): a phase 3 randomized controlled trial.BMC Cancer已检查 1 张 PMC Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram。PMID 41673604PMC129980962026-Feb-110.45This is a protocol for a phase 3 randomized controlled trial of memantine in patients undergoing craniospinal irradiation for brain tumors. While it meets the criteria for oncology, human, randomized, phase 3, and drug intervention, it is excluded because: 1) It is a protocol publication without reported results. 2) The primary endpoint, cognitive deterioration-free survival (CDFS), is a novel composite neurocognitive outcome, not a standard oncologic time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). 3) No Kaplan-Meier curves, hazard ratios, or other time-to-event efficacy data are provided. Therefore, the study cannot be considered for inclusion in the Kaplan-Meier digitization cohort.无 KM 图
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.J Am Coll CardiolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41143759无 PMCID2026-Feb-100.98未发现恶性肿瘤人群证据。无 KM 图
Targeted Oxygen for Initial Resuscitation of Preterm Infants: The TORPIDO 30/60 Randomized Clinical Trial.JAMA已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other。PMID 41369162PMC126966582026-Feb-100.98未发现恶性肿瘤人群证据。无 KM 图
Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41460638PMC127503342026-Feb-100.98未发现恶性肿瘤人群证据。无 KM 图
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.J Clin OncolPMID 41505697PMC128791912026-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial.BMJPMID 41667193PMC128877252026-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial.Nat CommunPMID 41667463PMC130029032026-Feb-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine.Clin Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 39879629无 PMCID2026-Feb-090.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.Clin Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40694627无 PMCID2026-Feb-090.98未发现恶性肿瘤人群证据。无 KM 图
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.Cancer CellAI 判定该论文不进入自动 KM 提取:The study is explicitly labeled as a Phase II trial in both the abstract and publication types, not Phase III.PMID 41349543无 PMCID2026-Feb-090.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。无 KM 图
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41654374无 PMCID2026-Feb-070.98未发现恶性肿瘤人群证据。无 KM 图
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41654375无 PMCID2026-Feb-070.98未发现恶性肿瘤人群证据。无 KM 图
Immunogenicity, safety, and lot consistency of the anthrax vaccine adsorbed, adjuvanted for post-exposure prophylaxis of anthrax in healthy adults: A phase 3, randomized, double-blind trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41401704无 PMCID2026-Feb-060.98未发现恶性肿瘤人群证据。无 KM 图
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41124201无 PMCID2026-Feb-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41160818无 PMCID2026-Feb-050.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Granisetron transdermal delivery system versus palonosetron in the prevention of long-delayed nausea and vomiting: a phase III randomized trial.Oncologist疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:研究设计图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:森林图/亚组分析图;Figure 5.:森林图/亚组分析图;另有 1 张未列出。PMID 41520166PMC129231112026-Feb-050.95The study is a Phase III randomized trial in oncology patients, but the primary endpoint is a categorical 'complete response rate' (vomiting and rescue medication use) during a specific time window, not a time-to-event outcome like OS or PFS. No Kaplan-Meier analysis or hazard ratio for a survival or progression endpoint is mentioned. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint for this cohort.无 KM 图
Feasibility of a phase 3 partially randomised clinical trial to assess the safety and efficacy of paediatric praziquantel for schistosomiasis treatment in children aged 3 months to 6 years in endemic regions of Brazil: a pilot study.BMJ Open入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41644160PMC128784672026-Feb-050.98未发现恶性肿瘤人群证据。无 KM 图
Does the Fissure Last Technique Really Reduce Postoperative Airleak After Lung Resection? Results From a Prospective Randomized Controlled Trial.Interdiscip Cardiovasc Thorac Surg疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 1.:非 KM 图;Figure 2.:非 KM 图。PMID 41689184PMC129274142026-Feb-050.93干预为非药物单独策略,未满足药物干预要求。无 KM 图
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide.N Engl J MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41879224无 PMCID2026-Feb-050.98未发现恶性肿瘤人群证据。无 KM 图
Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons.Clin Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 39928572无 PMCID2026-Feb-040.98未发现恶性肿瘤人群证据。无 KM 图
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years.Clin Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40464662无 PMCID2026-Feb-040.98未发现恶性肿瘤人群证据。无 KM 图
A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.Clin Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40577173无 PMCID2026-Feb-040.98未发现恶性肿瘤人群证据。无 KM 图
Automated Imaging as an Adjunct to Serum and Clinical Biomarkers: A New Validated Prediction Tool for Metastatic Castration-Resistant Prostate Cancer.Clin Cancer ResPMID 41324553PMC127589742026-Feb-040.70The record describes a study that develops a predictive model using data from two Phase III randomized trials (COU-AA-302 and A031201), but it is not the original formal result report of either trial. The title and abstract focus on model development and validation, not on reporting the primary efficacy results of a drug-containing intervention. The drug intervention is not explicitly named or evaluated in the abstract.已完成
Recombinant human growth hormone (rHGH) for muscle enhancement in knee osteoarthritis: protocol for a pilot, randomised placebo-controlled trial.BMJ Open入排复审未纳入:方案论文未报告临床试验结果。PMID 41638751PMC128784782026-Feb-040.97方案论文未报告临床试验结果。无 KM 图
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial.JAMAPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41205146PMC125967442026-Feb-030.98未发现恶性肿瘤人群证据。无 KM 图
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID Trial.J Nucl MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41266255无 PMCID2026-Feb-020.90The study is eligible for oncology, human, randomized, phase 3, and original results, but it is ineligible due to lack of a drug intervention and lack of a time-to-event efficacy endpoint. The intervention is diagnostic imaging, not a drug, and the endpoints are diagnostic/prognostic performance metrics, not survival outcomes.无 KM 图
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian cancer: a phase 3, double-blind, parallel group, randomized controlled pilot study.BMC MedPMID 41630017PMC129519862026-Feb-020.90The study is a randomized Phase III trial in human ovarian cancer with a drug intervention, but the primary endpoint is a binary toxicity outcome (CIPN incidence), not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). While survival is mentioned as a secondary endpoint, it is not the primary or key secondary focus, and no Kaplan-Meier or HR results are provided for a time-to-event efficacy outcome.已完成
Self-Acupressure for Fatigue in Patients Surviving Ovarian Cancer: A Randomized Clinical Trial.JAMA Netw Open已检查 2 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:CONSORT/入组流程图。PMID 41642626PMC128784372026-Feb-020.90The trial is a randomized, phase 3 oncology study in human patients with ovarian cancer, but the intervention is non-drug (self-acupressure via a mobile app) and the primary endpoint is change in fatigue (BFI), which is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). Therefore, it does not meet the criteria for inclusion.无 KM 图
Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw OpenPMID 41701495PMC129144902026-Feb-020.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial.Int J Radiat Oncol Biol PhysPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40876576无 PMCID2026-Feb-010.90The trial meets criteria for oncology, human, randomized, Phase III, and original result report with a drug intervention. However, it lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or any Kaplan-Meier or hazard ratio analysis, which is required for eligibility.无 KM 图
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41033612无 PMCID2026-Feb-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial.AIDS疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:AI 判定为 other。PMID 41037024PMC127467722026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.J Acquir Immune Defic Syndr疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 41081774无 PMCID2026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
The Portable Transcranial Electrical Stimulation and Internet-Based Behavioral Therapy for Major Depression Study (PSYLECT): Results of the maintenance phase.J Affect Disord入排复审未纳入:未发现恶性肿瘤人群证据。PMID 41284536无 PMCID2026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.JAMA OncolPMID 41343176PMC126794212026-Feb-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。已完成
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.JAMA Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1.:CONSORT/入组流程图;Figure 2.:非 KM 图;Figure 3.:非 KM 图。PMID 41379459PMC126993952026-Feb-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial.JAMA Ophthalmol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:非 KM 图;Figure 3.:森林图/亚组分析图;Figure 4.:非 KM 图。PMID 41411005PMC129215192026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
Mixed-Methods to Define Meaningful Change using Exit Interviewand Clinical Trial Data in Patients with Tenosynovial Giant Cell Tumor (TGCT).Qual Life Res入排复审未纳入:While the record is from a randomized Phase III oncology trial with a drug intervention, the reported results do not pertain to a time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints analyzed (PROMIS-PF, active ROM, stiffness) are patient-reported outcomes and functional measures, and the analysis defines responder thresholds for these, which falls under a secondary or methodological analysis, not the primary/key secondary time-to-event analysis required for inclusion.PMID 41621028PMC128619952026-Feb-010.85While the record is from a randomized Phase III oncology trial with a drug intervention, the reported results do not pertain to a time-to-event efficacy endpoint (e.g., OS, PFS). The endpoints analyzed (PROMIS-PF, active ROM, stiffness) are patient-reported outcomes and functional measures, and the analysis defines responder thresholds for these, which falls under a secondary or methodological analysis, not the primary/key secondary time-to-event analysis required for inclusion.无 KM 图
Efficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex.J Drugs DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41642149无 PMCID2026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.JAMA NeurolPMID 41661214PMC127235952026-Feb-010.98未发现恶性肿瘤人群证据。已完成
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study.Am J Respir Crit Care MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 41738096PMC130516932026-Feb-010.98未发现恶性肿瘤人群证据。无 KM 图
Patient-reported Quality of Life in PROFIT, a Phase 3 Randomized Clinical Trial Evaluating Moderately Hypofractionated Radiotherapy for Intermediate-risk Prostate Cancer.Eur Urol OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40335398无 PMCID2026-Feb0.95The study is a Phase III randomized trial in human oncology with original results, but it is ineligible because the intervention is non-drug-only (radiotherapy) and the primary efficacy endpoint is patient-reported quality of life, not a time-to-event endpoint.无 KM 图